You are here

Article Text

Article menu
Download PDFPDF
Community child health, public health, and epidemiology
Botulinum toxin for cerebral palsy; where are we now?
  1. R E Morton1,
  2. J Hankinson2,
  3. J Nicholson3
  1. 1Ronnie MacKeith Child Development Centre, Derbyshire Children’s’ Hospital, Derby and Nottingham Queens Medical Centre and City Hospital, Nottingham, UK
  2. 2Physiotherapy Department, Ronnie MacKeith Child Development Centre, Derby, UK
  3. 3Occupational Therapy department, Ronnie MacKeith Child Development Centre, Derby, UK
  1. Correspondence to:
    Dr R E Morton
    Ronnie MacKeith Child Development Centre, Derbyshire Children’s’ Hospital, Derby and Nottingham Queens Medical Centre and City Hospital, Nottingham, UK; richard.mortonsdah-tr.trent.nhs.uk

Abstract

In this article, the evidence base for botulinum-A treatment acquired in recent years is outlined, and the practicalities involved in providing this service are described. Botulinum-A is relatively new, and possible improvements for the future are considered.

  • BT-A, botulinum A
  • CP, cerebral palsy
  • RCT, randomised controlled trial
  • botulinum toxin
  • cerebral palsy

https://doi.org/10.1136/adc.2003.044560

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Funding: REM has received research grants from Ipsen, manufacturers of Dysport BT-A.